Ginsenoside Rg1

別名:Ginsenoside A2, Panaxoside A, Panaxoside Rg1, Sanchinoside C1, Sanchinoside Rg1

Ginsenoside Rg1 (Ginsenoside A2, Panaxoside A, Panaxoside Rg1, Sanchinoside C1, Sanchinoside Rg1), one of the major active components of ginseng, is identified as a protopanaxatriol-type and has pharmacological actions such as neuroprotective and anti-tumor effects on various cancer types. Ginsenoside Rg1 reduces cerebral Aβ levels and NF-κB nuclear translocation.

Ginsenoside Rg1化学構造

CAS No. 22427-39-0

サイズ 価格(税別) 在庫状況
JPY 22000 国内在庫あり
JPY 44500 国内在庫あり
JPY 82000 国内在庫あり

代表番号: 045-509-1970|電子メール:[email protected]
よく尋ねられる質問

文献中Selleckの製品使用例(2)

製品安全説明書

現在のバッチを見る: 純度: 99.18%
99.18

Ginsenoside Rg1関連製品

Beta Amyloid阻害剤の選択性比較

生物活性

製品説明 Ginsenoside Rg1 (Ginsenoside A2, Panaxoside A, Panaxoside Rg1, Sanchinoside C1, Sanchinoside Rg1), one of the major active components of ginseng, is identified as a protopanaxatriol-type and has pharmacological actions such as neuroprotective and anti-tumor effects on various cancer types. Ginsenoside Rg1 reduces cerebral Aβ levels and NF-κB nuclear translocation.
Targets
[5] NF-κB [6]
In Vitro
In vitro

Ginsenoside Rg1 (Rg1) activates promyogenic kinases, p38MAPK (mitogen-activated protein kinase) and Akt signaling, that in turn promotes the heterodimerization with MyoD and E proteins, resulting in enhancing myogenic differentiation. Through the activation of Akt/mammalian target of rapamycin pathway, Rg1 induces myotube growth and prevents dexamethasone-induced myotube atrophy. Furthermore, Rg1 increases MyoD-dependent myogenic conversion of fibroblast. Rg1 enhances glucose uptake in insulin-resistant myoblasts[1]. Rg1 possesses the capacity for anti-aging activity in HSCs both in vitro and vivo[2]. Ginsenoside Rg1 promotes endothelial progenitor cells (EPCs) adhesion, proliferation, migration and in vitro vasculogenesis in a dose- and time-dependent manner[3]. Ginsenoside Rg1 could prevent cellular apoptosis via initiating an autophagic survival response, during which time Rg1 could promote the expression of Beclin1 and Bcl-2 and weaken the interaction between Beclin1 and Bcl-2[4].

細胞実験 細胞株 Myoblast C2C12 cells
濃度 1, 5, 10, 50 nM
反応時間 2 days
実験の流れ

For the induction of myogenic differentiation, C2C12 cells are exchanged from growth medium (GM) containing 15% FBS to differentiation medium (DM) containing 2% HS. The efficiency of the myoblast differentiation is quantified. To induce hypertrophic myoblast differentiation, C2C12 cells are differentiated for 2 d and then treated with Rg1 for additional 2 days in DM. For the DEX-induced atrophy study, C2C12 cells are triggered to differentiate for 24 hrs and treated with 25 μM DEX and 10 nM Rg1, followed by incubation in DM for 2 days.

In Vivo
In Vivo

Rg1 can protect BMSCs against senescence and affect cell cycle phase distribution of bone marrow stromal cells (BMSCs) in aged rats. It affects inflammatory cytokine and stem cell factor (SCF) levels of BMSCs. Rg1 affects inflammatory cytokine and SCF levels of BMSCs. Rg1 improves the anti-aging ability of hematopoietic microenvironment through enhancing the anti-oxidant and anti-inflammatory capacities of BMSCs[2]. Rg1 has neuroprotective properties in neurodegenerative diseases such as AD. Rg1 could ameliorate cognitive impairment in the mouse model of AD, improve the learning and memory abilities, decrease the levels of cerebral Aβ, maintain hippocampal neuron activity, and prevent cellular apoptosis induced by Aβ accumulation. On the other hand, Rg1 also could protect against brain aging by enhancing the scavenging of free radicals in the brain[5].

動物実験 動物モデル male Sprague-Dawley rats
投与量 20 mg/kg·d
投与経路 i.p.

化学情報

分子量 801.01 化学式

C42H72O14

CAS No. 22427-39-0 SDF --
Smiles CC(=CCCC(C)(C1CCC2(C1C(CC3C2(CC(C4C3(CCC(C4(C)C)O)C)OC5C(C(C(C(O5)CO)O)O)O)C)O)C)OC6C(C(C(C(O6)CO)O)O)O)C
保管

In vitro
Batch:

モル濃度計算器

in vivo
Batch:

Add solvents to the product individually and in order.

投与溶液組成計算機

実験計算

モル濃度計算器

質量 濃度 体積 分子量

投与溶液組成計算機(クリア溶液)

ステップ1:実験データを入力してください。(実験操作によるロスを考慮し、動物数を1匹分多くして計算・調製することを推奨します)

mg/kg g μL

ステップ2:投与溶媒の組成を入力してください。(ロット毎に適した溶解組成が異なる場合があります。詳細については弊社までお問い合わせください)

% DMSO % % Tween 80 % ddH2O
%DMSO %

計算結果:

投与溶媒濃度: mg/ml;

DMSOストック溶液調製方法: mg 試薬を μL DMSOに溶解する(濃度 mg/mL, 注:濃度が当該ロットのDMSO溶解度を超える場合はご連絡ください。 )

投与溶媒調製方法:Take μL DMSOストック溶液に μL PEG300,を加え、完全溶解後μL Tween 80,を加えて完全溶解させた後 μL ddH2O,を加え完全に溶解させます。

投与溶媒調製方法:μL DMSOストック溶液に μL Corn oil,を加え、完全溶解。

注意:1.ストック溶液に沈殿、混濁などがないことをご確認ください;
2.順番通りに溶剤を加えてください。次のステップに進む前に溶液に沈殿、混濁などがないことを確認してから加えてください。ボルテックス、ソニケーション、水浴加熱など物理的な方法で溶解を早めることは可能です。

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

* 必須

大学・企業名を記入してください
名前を記入してください
電子メール・アドレスを記入してください 有効なメールアドレスを入力してください
お問い合わせ内容をご入力ください
Tags: Ginsenoside Rg1を買う | Ginsenoside Rg1 ic50 | Ginsenoside Rg1供給者 | Ginsenoside Rg1を購入する | Ginsenoside Rg1費用 | Ginsenoside Rg1生産者 | オーダーGinsenoside Rg1 | Ginsenoside Rg1化学構造 | Ginsenoside Rg1分子量 | Ginsenoside Rg1代理店